ADIL Q1 EPS Increased by Litchfield Hills Research

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) – Litchfield Hills Research increased their Q1 2025 earnings estimates for Adial Pharmaceuticals in a report issued on Tuesday, March 18th. Litchfield Hills Research analyst T. O’neill now forecasts that the company will post earnings of ($0.37) per share for the quarter, up from their previous estimate of ($0.40). The consensus estimate for Adial Pharmaceuticals’ current full-year earnings is ($1.53) per share. Litchfield Hills Research also issued estimates for Adial Pharmaceuticals’ Q2 2025 earnings at ($0.28) EPS, Q3 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.28) EPS and FY2025 earnings at ($1.22) EPS.

Adial Pharmaceuticals (NASDAQ:ADIL) last released its earnings results on Tuesday, March 4th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.38) by $0.23.

Adial Pharmaceuticals Stock Performance

Shares of ADIL opened at $0.72 on Thursday. Adial Pharmaceuticals has a fifty-two week low of $0.61 and a fifty-two week high of $3.10. The stock has a market capitalization of $4.73 million, a PE ratio of -0.22 and a beta of 1.13. The company’s fifty day moving average is $0.82 and its 200 day moving average is $0.97.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Renaissance Technologies LLC bought a new position in Adial Pharmaceuticals during the fourth quarter valued at $48,000. Citadel Advisors LLC grew its holdings in shares of Adial Pharmaceuticals by 63.8% in the fourth quarter. Citadel Advisors LLC now owns 54,508 shares of the company’s stock worth $55,000 after purchasing an additional 21,238 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Adial Pharmaceuticals by 36.0% in the fourth quarter. Geode Capital Management LLC now owns 61,847 shares of the company’s stock worth $62,000 after purchasing an additional 16,381 shares during the last quarter. Institutional investors own 16.41% of the company’s stock.

Adial Pharmaceuticals Company Profile

Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.